Skip to main content
All lobbying filings

The Procter and Gamble Company

The Procter and Gamble Company filed a Q1 report for The Procter and Gamble Company on April 20, 2026.

Lobbying for The Procter and Gamble Company

As filed: THE PROCTER AND GAMBLE COMPANY for THE PROCTER AND GAMBLE COMPANY.

All filings by The Procter and Gamble Company · Everything The Procter and Gamble Company has reported

 Filing · LD-2 quarterly report Q1 report
Reporting period
1st Quarter 2026
Jan 1 - Mar 31 · Posted Apr 20, 2026
Expenses
$818,900
What this organization spent lobbying with its own staff. Reported using IRS section 162(e) definitions (method C): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
District of Columbia

Official filing document

 Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 8
Pharmacy

-Issues related to FDA review of active ingredients in over-the-counter products

Health Issues

-Issues related to Generally Recognized as Safe (GRAS) and Additive Ingredients Regulation (no bill) -Issues related to New Approach Methodologies (NAMs) non-animal technologies used to evaluate drug safety and efficacy

Trade (domestic/foreign)

-Issues Related to the Review of the US-Mexico-Canada Trade Agreement (No Bill) -Section 232 Pharmaceuticals Trade Investigation -Section 232 Semiconductors Trade Investigation -Section 232 Softwood Lumber Trade Investigation -Section 232 Medical Devices/PPE Trade Investigation -IEEPA Reciprocal Tariffs -Section 232 Industrial Machinery Trade Investigation -Section 122 Balance of Payment Tariffs -Section 232 Steel/Aluminum Trade Investigation -Section 301 Excess Capacity/Forced Labor Trade Investigation -Issues related to counterfeit products/illicit trade

Consumer Issues/Safety/Products

-Issues Related to Product Safety and Quality Assurance (No Bill) -FDA Menstrual Products Guidance

Chemicals/Chemical Industry

-Issues related to updating the Toxic Substances Control Act (No Bill) -Implementation of Cybersecurity Reporting Law

Environment/Superfund

-Issues related to sustainability -H.R.7502-Pro Recycled Materials Attribution Act (RMAA) -H.R. 2269/S. 1092 - Wastewater Infrastructure Pollution Prevention and Environmental Safety (WIPPES) Act

Taxation/Internal Revenue Code

-OECD Digital Tax Project (Global Minimum Tax Implementation) -Implementation of H.R. 1 - One Big Beautiful Bill Act (Corporate/International Provisions) -Ongoing Negotiations of US Bilateral Tax Treaties -H.R. 1219 - Oral Health Products Inclusion Act

Foreign Relations

-Mexico Foreign Direct Investment Policies

 Bills named in this filing 4
  • H.R. 2269
    To provide for a limitation on availability of funds for US Department of Agriculture, Watershed and Flood Prevention O…
  • S. 1092
    WIPPES Act
  • H.R. 1
    One Big Beautiful Bill Act
  • H.R. 1219
    Oral Health Products Inclusion Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem